Navigation Links
ClinStar to Present on Russia's Performance as an Emerging Market in Global Clinical Trials

SAN FRANCISCO, Sept. 15, 2011 /PRNewswire/ -- ClinStar, LLC, an established CRO providing clinical research services in Russia and Eastern Europe to the pharmaceutical and biotechnology industry, announced today that Manager of Clinical Operations Alexander Kutermin will speak at VIBpharma's Outsourcing in Clinical Trials New England conference, September 28-29, at The Boston Park Plaza Hotel & Towers in Boston, MA.  


The paradigm of traditional drug development is shifting as more and more pharmaceutical and biotech organizations look to emerging markets to reduce their clinical study timelines, and hence overall development costs, through more effective patient enrollment. During the presentation scheduled for Wednesday, September 28 at 3:00 p.m., Mr. Kutermin will explore perceptions of emerging markets, evaluate Russia's clinical trial climate in comparison to other emerging countries and learn how to navigate Russia's regulations in order to ensure study success. The presentation will feature a real-life case study evaluating Russia's performance compared to two other regions in a global phase II clinical trial.

VIBpharma's Outsourcing in Clinical Trials New England conference prides itself in offering an expertly designed intelligence and networking platform to discuss pressing industry issues and provide practical solutions to the greatest challenges in clinical outsourcing. With more than 25 sessions, pharmaceutical and biotechnology participants at this year's conference will discuss unparalleled partnership strategies; value propositions in vendor selection; innovative methods to optimize patient enrollment; regulatory challenges; profitable budget management, trial costing and alternative pricing structures; expanded clinical development; emerging markets; and best practices for heightened vigilance in outsourced clinical trials.

About ClinStar, LLC

ClinStar is one of the most prominent CROs in the emerging markets of Eastern Europe and the Baltics with more than 10 years of expertise in Phase I-IV clinical studies in multiple therapeutic areas. Headquartered in San Francisco, California, ClinStar manages studies from its offices in Russia, Ukraine and Belarus, with total staff of over 260 people. Its portfolio contains over 130 clinical trials conducted for US and European pharmaceutical and biotechnology companies. More information is available at

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ClinStar, LLC Establishes New Office on the US East Coast
2. ClinStar to Present on Conducting Clinical Trials in Russia
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
5. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
10. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
11. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
Breaking Medicine News(10 mins):